Literature DB >> 7134835

Sclerosing cholangitis in ulcerative colitis. A follow-up study.

E Schrumpf, O Fausa, F Kolmannskog, K Elgjo, S Ritland, E Gjone.   

Abstract

In the 5-year period 1974-78, 48 (14%) of 336 patients with ulcerative colitis were found to have hepatobiliary disease. Endoscopic retrograde cholangiography (ERC) was successfully performed in 39 of these 48 patients, and sclerosing cholangitis was demonstrated in 19. One is excluded from this series because Crohn's disease was diagnosed at reclassification of the bowel disease. Two of the 18 patients with ulcerative colitis and sclerosing cholangitis have died, one of cholangiocarcinoma and one of an unrelated cause. The remaining 16 patients have been observed for a median period of 6 years (3-13 years) since the diagnosis of hepatobiliary disease. Ten have remained symptom-free, four have had intermittent or non-progressive symptoms, and two have developed symptoms of advanced chronic liver disease. The bilirubin level, which was initially raised in one of the patients, was elevated in four at the follow-up examination. Otherwise the laboratory values have remained stationary. Evidence of a progression of the hepatobiliary disease was found in most patients by repeated liver biopsy and particularly ERC. It is concluded that sclerosing cholangitis may remain asymptomatic for several years. Since progressive cholangiographic changes were often seen without concomitant worsening of symptoms, laboratory data, and liver biopsy findings, it is concluded that these criteria are of limited use in evaluating the progression of this disease.

Entities:  

Mesh:

Year:  1982        PMID: 7134835     DOI: 10.3109/00365528209181041

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  13 in total

1.  Segmental primary sclerosing cholangitis mimicking bile duct cancer--report of a case and review of the Japanese literature.

Authors:  T Tsunoda; T Eto; M Yamada; Y Tajima; S Matsuo; R Tsuchiya; T Shiozawa; T Matsuo
Journal:  Jpn J Surg       Date:  1991-05

Review 2.  Aetiology and natural history of primary sclerosing cholangitis--a decade of progress?

Authors:  R W Chapman
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

Review 3.  Primary sclerosing cholangitis.

Authors:  Y Ueno; N F LaRusso
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

4.  Microsatellite instability is absent in liver and biliary mucosa of patients with primary sclerosing cholangitis.

Authors:  S Y Jin; A E Noffsinger; P Bejarano; F L Weber; D W Hanto; J M Belli; C M Fenoglio-Preiser
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

5.  Colonic cancer in a patient with primary sclerosing cholangitis and long-standing ulcerative colitis.

Authors:  M Seo; M Okada; S Osamura; S Hara; T Umeno; K Maeshiro; Y Yamada; K Yuh
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

Review 6.  The pancreas and inflammatory bowel diseases.

Authors:  K R Herrlinger; E F Stange
Journal:  Int J Pancreatol       Date:  2000-06

7.  Liver histology and follow up of 68 patients with ulcerative colitis and normal liver function tests.

Authors:  U Broomé; H Glaumann; R Hultcrantz
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

8.  Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin.

Authors:  W J Sandborn; R H Wiesner; W J Tremaine; N F Larusso
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

9.  Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis.

Authors:  M Rabinovitz; A J Demetris; C F Bou-Abboud; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

10.  Symptomatic cerebral microangiopathy preceding initial manifestation of ulcerative colitis.

Authors:  C Dejaco; E Fertl; D Prayer; G Oberhuber; J Wyatt; C Gasché; A Gangl
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.